The world has made great progress against malaria in the last decade, but the fight is stalling for lack of funds, the World Health Organization’s annual report on malaria concluded on Monday. The amount spent on the disease by all countries rose to $1.8 billion last year, compared with $100 million in 2000, and, as a result, about one million children’s lives were probably spared over that time, the report said. But it would take $5 billion a year to get nets, insecticide spraying, diagnostic kits, effective drugs and hospital treatment to everyone needing them, and donor contributions, especially to the Global Fund to Fight AIDS, Tuberculosis and Malaria, have been nearly flat since 2010. Last year, the number of new nets purchased fell sharply, to 66 million from 145 million two years ago. Since nets wear out in three years and children are always being born, large numbers of infants and toddlers will soon be unprotected if more money does not come in, the report warned. The W.H.O. estimated that there were 219 million malaria cases in the world in 2010, with 660,00 deaths.
Biotech giant Amgen Inc. pleaded guilty to a federal misdemeanor of misbranding its anemia drug Aranesp and has agreed to pay $762 million in fines and penalties.
The Thousand Oaks company said it had reached a preliminary settlement of federal criminal and civil investigations last year and had already set aside about $780 million to resolve several related cases.
A spokesman for the U.S. attorney's office in Brooklyn said a federal judge is scheduled to hold another hearing on the settlement Wednesday.
Amgen said the "plea and sentence remain subject to judicial review and approval" and it expects to resolve the related civil and criminal matters once that process is complete.
Federal prosecutors accused Amgen of promoting Aranesp for uses that weren't approved by the U.S. Food and Drug Administration, a common claim brought by government officials against big pharmaceutical companies.
Amgen's shares were up 7 cents to $89.57 in mid-session trading Tuesday.
Aranesp, which is used primarily to treat anemia in cancer patients, generated sales of $2.3 billion last year. But sales of Amgen's anemia treatments have slumped in recent quarters due partly to safety concerns.
In recent years, federal prosecutors have aggressively pursued whistleblower fraud cases against large drug makers and won major settlements.
In July, GlaxoSmithKline agreed to plead guilty to federal charges and pay $3 billion in the largest healthcare-fraud settlement in U.S. history.
However, some critics say the government's enforcement efforts don't go far enough since the company executives involved usually don't face significant penalties or jail time.
ALSO:
Settlement points out Medicare's vulnerabilities
Medicare paid $1.5 billion in improper therapy claims in 2009
Blue Shield seeks rates hikes up to 20% amid record-high reserves
Follow Chad Terhune on Twitter









